[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

ATE409487T1 - Behandlung von morbus parkinson mit oligonukleotiden - Google Patents

Behandlung von morbus parkinson mit oligonukleotiden

Info

Publication number
ATE409487T1
ATE409487T1 AT99971323T AT99971323T ATE409487T1 AT E409487 T1 ATE409487 T1 AT E409487T1 AT 99971323 T AT99971323 T AT 99971323T AT 99971323 T AT99971323 T AT 99971323T AT E409487 T1 ATE409487 T1 AT E409487T1
Authority
AT
Austria
Prior art keywords
parkinson
disease
treatment
oligonucleotides
targeted
Prior art date
Application number
AT99971323T
Other languages
English (en)
Inventor
Jay Schneider
Original Assignee
Univ Jefferson
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Univ Jefferson filed Critical Univ Jefferson
Application granted granted Critical
Publication of ATE409487T1 publication Critical patent/ATE409487T1/de

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/70Carbohydrates; Sugars; Derivatives thereof
    • A61K31/7088Compounds having three or more nucleosides or nucleotides
    • A61K31/711Natural deoxyribonucleic acids, i.e. containing only 2'-deoxyriboses attached to adenine, guanine, cytosine or thymine and having 3'-5' phosphodiester links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/14Drugs for disorders of the nervous system for treating abnormal movements, e.g. chorea, dyskinesia
    • A61P25/16Anti-Parkinson drugs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09Recombinant DNA-technology
    • C12N15/11DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/113Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
    • C12N15/1137Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing against enzymes
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/10Type of nucleic acid
    • C12N2310/15Nucleic acids forming more than 2 strands, e.g. TFOs
    • C12N2310/152Nucleic acids forming more than 2 strands, e.g. TFOs on a single-stranded target, e.g. fold-back TFOs
    • CCHEMISTRY; METALLURGY
    • C12BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12NMICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2310/00Structure or type of the nucleic acid
    • C12N2310/30Chemical structure
    • C12N2310/31Chemical structure of the backbone
    • C12N2310/315Phosphorothioates

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Virology (AREA)
  • Neurology (AREA)
  • Epidemiology (AREA)
  • Biophysics (AREA)
  • Neurosurgery (AREA)
  • Microbiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Psychology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Saccharide Compounds (AREA)
AT99971323T 1998-11-05 1999-11-05 Behandlung von morbus parkinson mit oligonukleotiden ATE409487T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US10719198P 1998-11-05 1998-11-05

Publications (1)

Publication Number Publication Date
ATE409487T1 true ATE409487T1 (de) 2008-10-15

Family

ID=22315323

Family Applications (1)

Application Number Title Priority Date Filing Date
AT99971323T ATE409487T1 (de) 1998-11-05 1999-11-05 Behandlung von morbus parkinson mit oligonukleotiden

Country Status (8)

Country Link
US (2) US20030060436A1 (de)
EP (1) EP1135113B1 (de)
JP (1) JP2002528509A (de)
AT (1) ATE409487T1 (de)
CA (1) CA2350212A1 (de)
DE (1) DE69939663D1 (de)
ES (1) ES2317710T3 (de)
WO (1) WO2000025798A1 (de)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP1575510A4 (de) * 2002-08-07 2007-12-26 Univ Delaware Zusammensetzungen und verfahren zur behandlung von krankheiten mit protein-fehlanordnung und aggregation
EP1428875B1 (de) * 2002-12-13 2006-06-28 Centre National De La Recherche Scientifique (Cnrs) Verfahren zur Diagnose von Fettsucht
KR100616742B1 (ko) * 2004-02-27 2006-08-28 한국원자력연구소 글루타메이트 디카르복실라제 67의 안티센스 유전자를유효성분으로 포함하는 항암제, 상기 유전자를 포함하는발현 벡터 및 이를 형질도입한 형질전환체
WO2006013457A2 (en) * 2004-03-19 2006-02-09 Diamyd Medical Ab Gad2 gene for possible treatment of nervous system disorders
TWI809004B (zh) * 2017-11-09 2023-07-21 美商Ionis製藥公司 用於降低snca表現之化合物及方法
US11447775B2 (en) 2018-01-12 2022-09-20 Bristol-Myers Squibb Company Antisense oligonucleotides targeting alpha-synuclein and uses thereof
AU2022297513A1 (en) * 2021-06-23 2024-01-18 Enclear Therapies, Inc. Method of regulating gene expression

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE162198T1 (de) * 1992-07-27 1998-01-15 Hybridon Inc Oligonukleotid alkylphosphonothiate
US5929042A (en) * 1997-03-03 1999-07-27 The Trustees Of Columbia University In The City Of New York Antisense compounds which prevent cell death and uses thereof

Also Published As

Publication number Publication date
ES2317710T3 (es) 2009-04-16
US20050020530A1 (en) 2005-01-27
WO2000025798A1 (en) 2000-05-11
CA2350212A1 (en) 2000-05-11
US20030060436A1 (en) 2003-03-27
WO2000025798A8 (en) 2002-01-17
JP2002528509A (ja) 2002-09-03
EP1135113A4 (de) 2004-12-22
EP1135113A1 (de) 2001-09-26
DE69939663D1 (de) 2008-11-13
EP1135113B1 (de) 2008-10-01
US7414034B2 (en) 2008-08-19

Similar Documents

Publication Publication Date Title
Wallace et al. The amygdalo-brainstem pathway: selective innervation of dopaminergic, noradrenergic and adrenergic cells in the rat
Zangen et al. Association between depressive behavior and absence of serotonin–dopamine interaction in the nucleus accumbens
Nambu et al. Excitatory cortical inputs to pallidal neurons via the subthalamic nucleus in the monkey
Sessle Neural mechanisms and pathways in craniofacial pain
Al-Majed et al. Electrical stimulation accelerates and enhances expression of regeneration-associated genes in regenerating rat femoral motoneurons
RU2008121750A (ru) Ионофоретическая доставка ротиготина для лечения болезни паркинсона
EP2139475B1 (de) PDE7-Inhibitoren zur Verwendung bei der Behandlung von Bewegungsstörungen
DE69939663D1 (de) Behandlung von morbus parkinson mit oligonukleotiden
WO2004089353A3 (en) Methods for treatment of parkinson's disease
ATE207352T1 (de) Nicht-allosterische gaba a agonisten zur behandlung von schlafstörungen
DE60106763D1 (de) Glutaminsäure decarboxylase (gad) abgabesystem zur behandlung neurodegeneraliver erkrankungen
Rodríguez-Manzo et al. Stimulation of the medial preoptic area facilitates sexual behavior but does not reverse sexual satiation.
HUP0102511A2 (hu) Kombinált gyógykezelés bipoláris betegségek kezelésére
Da Prada et al. The effect of 5, 6-dihydroxytryptamine on sexual behaviour of male rats
ATE355054T1 (de) Verfahren und verbindungen zur behandlung der depression
Drake et al. Pain in Parkinson's disease: pathology to treatment, medication to deep brain stimulation
Gnanalingham et al. Chronic continuous and intermittentl-3, 4-dihydroxyphenylalanine treatments differentially affect basal ganglia function in 6-hydroxydopamine lesioned rats—an autoradiographic study using [3H] flunitrazepam
Patz et al. Neurotrophins induce short‐term and long‐term changes of cortical neurotrophin expression
Guo et al. The effect of electroacupuncture on spontaneous recurrent seizure and expression of GAD67 mRNA in dentate gyrus in a rat model of epilepsy
Lees Levodopa substitution: the gold standard
JP2002528509A5 (de)
CA2525524A1 (en) Combination of the analeptic modafinil and an antidepressant for the treatment of depression
Meissner et al. Impact of chronic subthalamic high‐frequency stimulation on metabolic basal ganglia activity: a 2‐deoxyglucose uptake and cytochrome oxidase mRNA study in a macaque model of Parkinson's disease
Blanco et al. Up‐regulation of brain‐derived neurotrophic factor by application of fibroblast growth factor‐2 to the cut optic nerve is important for long‐term survival of retinal ganglion cells
Nielsen et al. Dual effects of intermittent or continuous L‐DOPA administration on gene expression in the globus pallidus and subthalamic nucleus of adult rats with a unilateral 6‐OHDA lesion

Legal Events

Date Code Title Description
RER Ceased as to paragraph 5 lit. 3 law introducing patent treaties